Allopurinol in the prevention of hyperuricaemia secondary to the treatment of neoplastic diseases with alkylating agents, adrenal steroids, and radiation therapy.
D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use; D002247:Carbon Isotopes; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D057487:Enzyme Therapy; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007890:Leiomyosarcoma / Q000628:therapy; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D011687:Purines / Q000652:urine; D011878:Radiotherapy; D014527:Uric Acid / Q000097:blood* / Q000652:urine; D014528:Uricosuric Agents / Q000627:therapeutic use*; D014969:Xanthine Oxidase; D014970:Xanthines / Q000652:urine
D002247:Carbon Isotopes; D011687:Purines; D014528:Uricosuric Agents; D014970:Xanthines; D014527:Uric Acid; D000493:Allopurinol; D003520:Cyclophosphamide; D014969:Xanthine Oxidase; D011241:Prednisone; D006854:Hydrocortisone